Olmesartan
Olmesartan
Klass : 3
Visa all info
Skriv ut
Kontakta oss
Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.
Shimada C, Akaishi R, Cho K, Morikawa M, Kaneshi Y, Yamda T et al. Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review. Hypertens Res. 2015;38(5):308-13.
Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005;73:123-30.
Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te Winkel B et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141.
Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009;65:615-25.
Fu J, Tomlinson G, Feig DS. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis. Diabetes Metab Res Rev. 2021;37(8):e3453.
Celentano C, Prefumo F, di Vera E, Iannicco A, Gallo DP, Liberati M. Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker. Pediatr Nephrol. 2008;23(2):333-4.
Georgaki-Angelaki E, Stergiou N, Naoum E, Papassotiriou I, Anagnostakou M. Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature. NDT Plus. 2009;2(4):295-7.
Hünseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, Körber F et al. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr. 2011;223(1):10-4.
Spaggiari E, Heidet L, Grange G, Guimiot F, Dreux S, Delezoide AL et al. Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers. Prenat Diagn. 2012;32(11):1071-6.
Gang MH, Lee YW, Chang MY. Secondary renal tubular dysgenesis in a newborn exposed to angiotensin Ⅱ receptor antagonist during gestation. Clin Exp Pediatr. 2021;64(3):136-138.
- Briggs G, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 11th ed; 2017.
- Shimada C, Akaishi R, Cho K, Morikawa M, Kaneshi Y, Yamda T et al. Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review. Hypertens Res. 2015;38(5):308-13.
- Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005;73:123-30.
- Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
- Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te Winkel B et al. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens. 2020;38(1):133-141.
- Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009;65:615-25.
- Fu J, Tomlinson G, Feig DS. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis. Diabetes Metab Res Rev. 2021;37(8):e3453.
- Celentano C, Prefumo F, di Vera E, Iannicco A, Gallo DP, Liberati M. Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker. Pediatr Nephrol. 2008;23(2):333-4.
- Georgaki-Angelaki E, Stergiou N, Naoum E, Papassotiriou I, Anagnostakou M. Olmesartan medoxomil-induced acute renal failure in a premature newborn following maternal exposure during pregnancy: a case report and review of the literature. NDT Plus. 2009;2(4):295-7.
- Hünseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, Körber F et al. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr. 2011;223(1):10-4.
- Spaggiari E, Heidet L, Grange G, Guimiot F, Dreux S, Delezoide AL et al. Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers. Prenat Diagn. 2012;32(11):1071-6.
- Gang MH, Lee YW, Chang MY. Secondary renal tubular dysgenesis in a newborn exposed to angiotensin Ⅱ receptor antagonist during gestation. Clin Exp Pediatr. 2021;64(3):136-138.